
Acticor Biotech
MABDESIGN MEMBER
About us
Acticor Biotech is a spin-off of Inserm (French National Institute of Health and Medical Research). Founded in late 2013 it is dedicated to the development of an new antithrombotic drug for ischemic stroke. The product is a humanized fragment (Fab) of antibody directed against a new target of major interest: the platelet glycoprotein VI (GPVI).
Field of application
- antibodies
Therapeutic application
- cardiology
Expertise
- Assay development in in-vitro & in-vivo models
- Master Cell Bank
- Production
- Characterization
- Storage
- Phase I
- Phase II
Category
- Therapeutic product
Contact
- Gilles Avenard
CEO - INSERM U1148 - Hôpital Bichat
46 rue Henri Huchard 75018 Paris - +33609166850
- gilles.avenard@acticor-biotech.com
- www.acticor-biotech.com